Page 6 - Juergen Eckhardt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bayer leads $40m investment in Israeli biotech co Ukko The funding will allow Ukko to begin clinical trials on its peanut allergy therapy and develop is celiac and gluten sensitivity treatment. Israeli biotech company Ukko, which is working to eliminate food allergies and sensitivities, today announced the completion of a $40 million Series B financing round. The round was led by Bayer's impact investment arm Leaps, with the participation of Continental Grain Company, PeakBridge Ventures, Skyviews Life Science and Fall Line Capital, and existing investors Khosla Ventures, Innovation Endeavors...

Bayer plans 3 new drugs, banks on gene and cell therapy allogeneic cancer medicines PUBLISHED BY Bayer has plans to introduce three news drugs with annual sales potential of $1.22 billion (€1 billion) but these will not offset the fall in revenue the company anticipates from the loss of patents over its two best-sellers. Stefan Oelrich, the company head, who joined in 2018 from rival Sanofi, acknowledged that the new drugs would not compensate for the effects of the forthcoming patent expiry on both its blood thinner Xarelto and eye medicine Eylea, which will start this year in stages ...

(2) Senti Bio's gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Additional investors inclu...

Dive Brief: Bayer's venture investment arm is leading a $105 million funding round in closely held Senti Biosciences, a California-based company using synthetic biology to develop off-the-shelf cell therapies for cancer. It is at least the third cell therapy company to receive investment from Bayer, which has since acquired one of those companies. Senti is advancing two experimental treatments using "natural killer" immune cells to attack tumors in leukemia and liver cancer. The company believes its technology can create treatments with greater precision and control than current cell therapie...

Press release content from Business Wire. The AP news staff was not involved in its creation. Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority December 18, 2020 GMT SAN FRANCISCO & NESS ZIONA, Israel--(BUSINESS WIRE)--Dec 18, 2020-- Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration wil...